secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2026-07-06T11:00:40+00:00
Accession:  0001104659-26-080562
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron expects ~$127M IPR&D charge in Q2 2026, reducing EPS by ~$1.00
------------------------------------------------------------------------

- Pre-tax acquired IPR&D charge of ~$127M from collaboration and licensing up-front/opt-in payments.
- Charge expected to reduce both GAAP and non-GAAP diluted EPS by ~$1.00 in Q2 2026.
- Q2 2026 results not finalized; subject to financial statement closing procedures.
- Company does not forecast such IPR&D charges due to uncertainty of timing and magnitude.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/0001104659-26-080562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-080562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer